Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2006

01-07-2006 | Original Article

Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen

Authors: Irma M. Sainz, Irma Isordia-Salas, Ricardo G. Espinola, Walter K. Long, Robin A. Pixley, Robert W. Colman

Published in: Cancer Immunology, Immunotherapy | Issue 7/2006

Login to get access

Abstract

Multiple myeloma (MM), a B-cell malignancy characterized by proliferation of monoclonal plasma cells remains incurable. Murine plasma cell tumors share common features with human MM. We used two cell lines (B38 and C11C1) derived from P3X63Ag8 myeloma cells. The new cell lines were implanted subcutaneously in the strain of origin (Balb/c mice) and used as a model to monitor the effects of C11C1 monoclonal antibody (mAb) to kininogen (HK). We assessed their behavior by intraperitoneal and subcutaneous implantation, by implanting them together and by treating B38–MM with purified mAb C11C1. We evaluated growth, microvascular density (MVD), and cellular expression of urokinase-type plasminogen activator-receptor (uPAR), fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), bradykinin-1 receptor (B1R), bradykinin-2 receptor (B2R) and HK. We found that both MM-cell-lines are uPAR positive, that mAb C11C1 inhibits its own tumor growth in vivo, slows down B38-MM growth rate when both MM are implanted together and when mAb C11C1 is injected intraperitoneally. MAb C11C1-treated-MM showed decreased MVD and HK binding in vivo without FGF-2, B1R or B2R expression changes. We propose that the B38-extramedullary-myeloma-model is a useful tool to study the interactions of this hematopoietic tumor and its environment and that mAb C11C1 may improve the efficacy of conventional MM treatment with minimal side effects.
Literature
1.
Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927–937CrossRefPubMed
2.
Criteria for the classification of monoclonal gammopathies, (2003) multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–57
3.
Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C, Stoppa AM, Gastaut JA (2004) Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol 73:402–406CrossRefPubMed
4.
Roschke V, Hausner P, Kopantzev E, Pumphrey JG, Riminucci M, Hilbert DM, Rudikoff S (1998) Disseminated growth of murine plasmacytoma: similarities to multiple myeloma. Cancer Res 58:535–541PubMed
5.
Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, Guo YL, Pixley RA, Reddy EP, Colman RW (2004) Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 104:2065–2072CrossRefPubMed
6.
Annamalai AE, Stewart GJ, Hansel B, Memoli M, Chiu HC, Manuel DW, Doshi K, Colman RW (1986) Expression of factor V on human umbilical vein endothelial cells is modulated by cell injury. Arteriosclerosis 6:196–202PubMed
7.
Schmaier AH, Schutsky D, Farber A, Silver LD, Bradford HN, Colman RW (1987) Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 262:1405–1411PubMed
8.
Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105:20–23CrossRefPubMed
9.
Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761CrossRefPubMed
10.
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484CrossRef
11.
12.
Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, Kroger M, Mesters RM, Berdel WE, Kienast J (2003) Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 101:2775–2783CrossRefPubMed
13.
Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F (1993) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064–3073
14.
Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV (2003) Expression of VEGF and its receptors by myeloma cells. Leukemia 17:2025–2031CrossRefPubMed
15.
Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMed
16.
Gardner AM, Olah ME (2003) Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A2A adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells. J Biol Chem 278:15421–15428CrossRefPubMed
17.
Knox AJ, Corbett L, Stocks J, Holland E, Zhu YM, Pang L (2001) Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J 15:2480–2488CrossRefPubMed
18.
Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629–5639PubMed
19.
Mazure NM, Chen EY, Laderoute KR, Giaccia AJ (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90:3322–3331PubMed
20.
Basilico C, Moscatelli D (1992) The FGF family of growth factors and oncogenes. Adv Cancer Res 59:115–165PubMed
21.
Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161–195PubMed
22.
Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB (1993) Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 4:973–982PubMed
23.
Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y (2003) Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 63:2037–2041PubMed
24.
Barki-Harrington L, Bookout AL, Wang G, Lamb ME, Leeb-Lundberg LM, Daaka Y (2003) Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochem J 371:581–587CrossRefPubMed
25.
Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, Muller-Esterl W, Maeda H (2002) Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 98:29–35CrossRefPubMed
26.
Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K, Yamashina S, Tsutsumi Y, Matsubara H, Majima M (2004) Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 64:5178–5185CrossRefPubMed
27.
Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC (2001) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28:607–612CrossRefPubMed
28.
Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier AH (2001) Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 280:H1821–H1829PubMed
29.
Hayashi I, Amano H, Yoshida S, Kamata K, Kamata M, Inukai M, Fujita T, Kumagai Y, Furudate S, Majima M (2002) Suppressed angiogenesis in kininogen-deficiencies. Lab Invest 82:871–880PubMed
30.
Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR (1997) Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100:1481–1487PubMed
31.
Mahdi F, Shariat-Madar Z, Kuo A, Carinato M, Cines DB, Schmaier AH (2004) Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem 279:16621–16628CrossRefPubMed
32.
Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noel A (2003) Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 60:463–473CrossRefPubMed
33.
Mondino A, Blasi F (2004) uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25:450–455CrossRefPubMed
34.
Venema VJ, Marrero MB, Venema RC (1996) Bradykinin-stimulated protein tyrosine phosphorylation promotes endothelial nitric oxide synthase translocation to the cytoskeleton. Biochem Biophys Res Commun 226:703–710CrossRefPubMed
35.
Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC (2001) Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 276:16587–16591CrossRefPubMed
36.
Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100:3131–3139PubMedCrossRef
37.
Hayashi R, Yamashita N, Matsui S, Fujita T, Araya J, Sassa K, Arai N, Yoshida Y, Kashii T, Maruyama M, Sugiyama E, Kobayashi M (2000) Bradykinin stimulates IL-6 and IL-8 production by human lung fibroblasts through ERK- and p38 MAPK-dependent mechanisms. Eur Respir J 16:452–458CrossRefPubMed
38.
Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, Wilke CA, Strieter RM (1994) Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179:1409–1415CrossRefPubMed
39.
Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM (1996) Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97:2792–2802PubMed
40.
Yuan A, Chen JJ, Yao PL, Yang PC (2005) The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 10:853–865PubMedCrossRef
41.
Tobler A, Moser B, Dewald B, Geiser T, Studer H, Baggiolini M, Fey MF (1993) Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 82:2517–2525PubMed
42.
Jonca F, Ortega N, Gleizes PE, Bertrand N, Plouet J (1997) Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J Biol Chem 272:24203–24209CrossRefPubMed
43.
Ribatti D, Leali D, Vacca A, Giuliani R, Gualandris A, Roncali L, Nolli ML, Presta M (1999) in vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J Cell Sci 112 (Pt 23):4213–4221PubMed
44.
Ossowski L, Clunie G, Masucci MT, Blasi F (1991) in vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115:1107–1112CrossRefPubMed
45.
Chapman HA (1997) Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9:714–724CrossRefPubMed
46.
Nehls V, Herrmann R (1996) The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration. Microvasc Res 51:347–364CrossRefPubMed
47.
Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN, Powell JA, Jr Mousa SA (2003) Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 1:164–170CrossRefPubMed
48.
Colman RW (1992) Contributions of Mayme Williams to the elucidation of the multiple functions of plasma kininogens. Thromb Haemost 68:99–101PubMed
Metadata
Title
Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen
Authors
Irma M. Sainz
Irma Isordia-Salas
Ricardo G. Espinola
Walter K. Long
Robin A. Pixley
Robert W. Colman
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 7/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0068-8

Other articles of this Issue 7/2006

Cancer Immunology, Immunotherapy 7/2006 Go to the issue

Original Article

Defining MHC class II T helper epitopes for WT1 tumor antigen

Original Article

Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer

Original Article

A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA–A24 carcinoma cells

Original Article

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC)

Original Article

MAGE-1/Heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo

Original Article

Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits